Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 239 results for children's cancer

  1. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (TA1116)

    Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.

  2. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  3. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  4. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

  5. Sole supplied titles

    Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.

  6. Fertility clinics must end unproven treatments that don't help couples have babies

    Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.

  7. Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in under 16s (not pregnant or recently pregnant). It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  8. Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management (NG255)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  9. Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  10. Into practice resources

    Resources, case studies and patient decision aids to show how you can use evidence to improve care and services

  11. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  12. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  13. Past appeals and decisions

    Past technology appraisal appeals and decisions

  14. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

  15. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members